Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Adicet Bio (NASDAQ: ACET) will host an R&D webcast on November 10, 2022, at 9:00 AM EST, providing a pipeline overview.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Adicet to Host R&D Webcast Event on
Poster Presentations:
Abstract Title: Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy
Poster/Abstract Number: 198
Presenting Author:
Date/Time:
Title: Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer
Poster/Abstract Number: 203
Presenting Author:
Date/Time:
Abstract Title: Allogeneic “off-the-shelf” γδ T cells modified with CD27- containing CAR for targeting CD70+ cancers
Poster/Abstract Number: 246
Presenting Author:
Date/Time:
Abstract Title: Preclinical Discovery and Evaluation of Allogeneic “off-the-shelf” γδ CAR T Cells Targeting B7-H6+ Tumors
Poster/Abstract Number: 247
Presenting Author:
Date/Time:
The abstracts will be available in a
R&D Webcast
Adicet will host an R&D webcast presentation on
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005195/en/
Investor and Media Contacts
abowdidge@adicetbio.com
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com
Source: